AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9449495 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release theophylline (doses adjusted for optimum control, twice per day)
Number of subjects: 747
Study 7875922 — intervention group
Group type: EXPERIMENTAL
Intervention: Carleton Skills Training Program (CSTP)
Number of subjects: 0
Study 7875922 — intervention group
Group type: COMPARATOR
Intervention: Modified training program (without physical enactment instructions)
Number of subjects: 0
Study 7875922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training programs
Number of subjects: 0
Study 7875922 — intervention group
Group type: EXPERIMENTAL
Intervention: CSTP
Number of subjects: 0
Study 7875922 — intervention group
Group type: COMPARATOR
Intervention: Modified training program
Number of subjects: 0
Study 2212369 — intervention group
Group type: EXPERIMENTAL
Intervention: single pathway monophasic pulsing
Number of subjects: 12
Study 2212369 — intervention group
Group type: EXPERIMENTAL
Intervention: single pathway biphasic pulsing
Number of subjects: 12
Study 2212369 — intervention group
Group type: EXPERIMENTAL
Intervention: dual pathway sequential pulsing
Number of subjects: 12
Study 2212369 — intervention group
Group type: EXPERIMENTAL
Intervention: dual pathway simultaneous pulsing
Number of subjects: 12
Study 2212369 — intervention group
Group type: EXPERIMENTAL
Intervention: best pulsing technique for each patient
Number of subjects: 12
Study 2212369 — intervention group
Group type: EXPERIMENTAL
Intervention: transvenous defibrillation techniques
Number of subjects: 12
Study 2212369 — intervention group
Group type: COMPARATOR
Intervention: one transvenous defibrillation method
Number of subjects: 12
Study 105777 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (ED group)
Number of subjects: 30
Study 105777 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 30
Study 31352029 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABM training shifting attention away from threat
Number of subjects: 32
Study 31352029 — intervention group
Group type: COMPARATOR
Intervention: Attention control training involving no attention modification
Number of subjects: 32
Study 29211950 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% NaHCO3 plus 1425 ppm fluoride (F) as sodium fluoride (NaF)
Number of subjects: 115
Study 29211950 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% NaHCO3 plus 1425 ppm fluoride (F) as sodium fluoride (NaF)
Number of subjects: 115
Study 29211950 — intervention group
Group type: COMPARATOR
Intervention: 0% NaHCO3 plus silica and 1450 ppm fluoride (F) as sodium fluoride (NaF)
Number of subjects: 115
Study 29211950 — intervention group
Group type: COMPARATOR
Intervention: 0% NaHCO3 plus silica and 1400 ppm fluoride (F) as amine F/stannous F
Number of subjects: 115
Study 29211950 — intervention group
Group type: COMPARATOR
Intervention: 0% NaHCO3 plus chlorhexidine/aluminum lactate and silica with 1360 ppm fluoride (F) as aluminum F
Number of subjects: 115
Study 25733317 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (10-15 mg/day for 6 months)
Number of subjects: 98
Study 23540545 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control arm (n = 128)
Number of subjects: 250
Study 23540545 — intervention group
Group type: COMPARATOR
Intervention: Rate control arm (n = 2,027)
Number of subjects: 250
Study 23540545 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control arm without PM (n = 1,905)
Number of subjects: 250
Study 21700416 — intervention group
Group type: EXPERIMENTAL
Intervention: Eco‐CIMT for 2h a day over a period of two months
Number of subjects: 25
Study 21700416 — intervention group
Group type: COMPARATOR
Intervention: Control period (ordinary treatment)
Number of subjects: 25
Study 19565732 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application of Chinese medicine at Dazhui (GV 14), Feishu (BL 13), Gaohuang (BL 43), Danzhong (CV 17), Qihai (CV 6)
Number of subjects: 100
Study 19565732 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture at Zhongfu (LU 1), Tiantu (CV 22), Danzhong (CV 17), Dingchuan (EX‐B 1), Fenglong (ST 40)
Number of subjects: 100
Study 16890688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg daily)
Number of subjects: 0
Study 16890688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15017450 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone social support and education over a 12-month period
Number of subjects: 17
Study 15017450 — intervention group
Group type: COMPARATOR
Intervention: Education through mailed resource kits only (Control)
Number of subjects: 17
Study 11373411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenercept (0.125 mg/kg intravenous)
Number of subjects: 1342
Study 11373411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1342
Study 9266384 — intervention group
Group type: EXPERIMENTAL
Intervention: New amino acid formulation and treatment products
Number of subjects: 25
Study 8518240 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum X-ray pelvimetry (XRP) at 36 weeks gestation
Number of subjects: 306
Study 8518240 — intervention group
Group type: COMPARATOR
Intervention: Trial labour without antepartum XRP (Control)
Number of subjects: 306
Study 8518240 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate antepartum XRP
Number of subjects: 306
Study 8518240 — intervention group
Group type: COMPARATOR
Intervention: Inadequate postpartum XRP in control group
Number of subjects: 306
Study 8518240 — intervention group
Group type: COMPARATOR
Intervention: Adequate postpartum XRP in control group
Number of subjects: 306
Study 8518240 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight of infants
Number of subjects: 306
Study 8518240 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal morbidity
Number of subjects: 306
Study 8518240 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal morbidity
Number of subjects: 306
Study 8518240 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and perinatal mortality
Number of subjects: 306
Study 3319111 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced sodium diet
Number of subjects: 100
Study 3319111 — intervention group
Group type: COMPARATOR
Intervention: Normal salt diet
Number of subjects: 100
Study 29505812 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 104
Study 29505812 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 104
Study 27582287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary orthognathic surgery (Le Fort I osteotomy and mandibular setback)
Number of subjects: 20
Study 24737678 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioguanine treatment arm (CCG‐1952 clinical trial)
Number of subjects: 351
Study 24737678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MTHFR and TPMT variant genotypes
Number of subjects: 351
Study 22420475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mL)
Number of subjects: 90
Study 22420475 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (1 mL)
Number of subjects: 90
Study 22420475 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 mL)
Number of subjects: 90
Study 20709127 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who ate in the dark with super-size portions
Number of subjects: 64
Study 20709127 — intervention group
Group type: COMPARATOR
Intervention: Participants who ate in the dark with regular portions
Number of subjects: 64
Study 20709127 — intervention group
Group type: COMPARATOR
Intervention: Control group (ate the same meal in the light)
Number of subjects: 64
Study 18853588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Prongs (NP)
Number of subjects: 37
Study 18853588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal Oxygen (NPO)
Number of subjects: 37
Study 18853588 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask (FM)
Number of subjects: 37
Study 15683110 — intervention group
Group type: EXPERIMENTAL
Intervention: ReoPro-coated stent
Number of subjects: 155
Study 15683110 — intervention group
Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 155
Study 11429337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion at 1.3 +/- 0.4 microg.kg(-1).min(-1)
Number of subjects: 9
Study 11429337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion
Number of subjects: 9
Study 11429337 — intervention group
Group type: COMPARATOR
Intervention: Concurrent infusion of phenylephrine
Number of subjects: 9
Study 9531030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin fragment 1+2 (F1+2) assay
Number of subjects: 159
Study 9531030 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin antithrombin III complexes (TAT) assay
Number of subjects: 159
Study 9531030 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer assay
Number of subjects: 159
Study 9531030 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU t.i.d.)
Number of subjects: 159
Study 9531030 — intervention group
Group type: COMPARATOR
Intervention: Desirudin (10, 15 or 20 mg b.i.d.)
Number of subjects: 159
Study 8602905 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum dentifrice (1.3% soluble pyrophosphate and 1.5% copolymer)
Number of subjects: 85
Study 8602905 — intervention group
Group type: COMPARATOR
Intervention: Crest Tartar Control dentifrice (5% soluble pyrophosphate)
Number of subjects: 85
Study 8602905 — intervention group
Group type: COMPARATOR
Intervention: Low abrasive dentifrice
Number of subjects: 85
Study 2737311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular analgesics given at fixed hours (methadone 10 mg i.m. every 12 h for days 1-3; sodium diclofenac 75 mg i.m. every 12 h for days 4-7)
Number of subjects: 35
Study 2737311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular analgesics given at fixed hours
Number of subjects: 35
Study 2737311 — intervention group
Group type: COMPARATOR
Intervention: Drugs 'on demand' or not treated at all
Number of subjects: 35
Study 342618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 virus vaccines (200, 400, or 800 chick cell-agglutinating units)
Number of subjects: 199
Study 342618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 virus vaccines (all dosages)
Number of subjects: 199
Study 342618 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 virus vaccines
Number of subjects: 199
Study 30472196 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels < 45 ng/L
Number of subjects: 120
Study 30472196 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels (continuous variable)
Number of subjects: 120
Study 28683017 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (1-hour PowerPoint presentation and video)
Number of subjects: 69
Study 28683017 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (PowerPoint presentation and video showing traditional demonstration)
Number of subjects: 69
Study 28683017 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 69
Study 25735317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) added to standard chemotherapy (CT)
Number of subjects: 376
Study 25735317 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (CT) only
Number of subjects: 376
Study 24968500 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection lignocaine (preservative free) 1.5 mg/kg i.v.
Number of subjects: 60
Study 24968500 — intervention group
Group type: COMPARATOR
Intervention: Oral pregabalin 150 mg capsule
Number of subjects: 60
Study 21300952 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 9166
Study 21300952 — intervention group
Group type: COMPARATOR
Intervention: Delayed provisional use of eptifibatide
Number of subjects: 9166
Study 19233341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg every other day)
Number of subjects: 22071
Study 19233341 — intervention group
Group type: EXPERIMENTAL
Intervention: Any aspirin use (self-selected)
Number of subjects: 22071
Study 16520405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic arm (impedance cardiography)
Number of subjects: 164
Study 16520405 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 164
Study 14708242 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentos
Number of subjects: 46
Study 14708242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 11571919 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum splints
Number of subjects: 33
Study 11571919 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel splints
Number of subjects: 33
Study 11571919 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 33
Study 9290024 — intervention group
Group type: EXPERIMENTAL
Intervention: Early alterations observed if acute renal failure (ARF) lasted for 1-10 days
Number of subjects: 64
Study 9290024 — intervention group
Group type: EXPERIMENTAL
Intervention: Late kidney alterations observed if ARF lasted for 11-20 days
Number of subjects: 64
Study 9290024 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed alterations observed if ARF lasted for 21-62 days
Number of subjects: 64
Study 8080611 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 micrograms BD for eight weeks
Number of subjects: 14
Study 8080611 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for four weeks
Number of subjects: 14
Study 2947537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone 0.5 g
Number of subjects: 204
Study 2947537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone 1.0 g
Number of subjects: 204
Study 2947537 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin 2.0 g
Number of subjects: 204
Study 30569984 — intervention group
Group type: EXPERIMENTAL
Intervention: CrCo-Ti rods
Number of subjects: 59
Study 30569984 — intervention group
Group type: COMPARATOR
Intervention: Ti-Ti rods
Number of subjects: 59
Study 30569984 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rod types
Number of subjects: 59
Study 27881338 — intervention group
Group type: EXPERIMENTAL
Intervention: Guifu Dihuang Wan (GFDHW) with lifestyle intervention
Number of subjects: 62
Study 27881338 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle intervention only)
Number of subjects: 62
Study 24411805 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target breath alcohol concentration of 0.08%)
Number of subjects: 236
Study 24411805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 24312450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte-predominant breast cancer (LPBC)
Number of subjects: 313
Study 24312450 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal lymphocytes (strLy)
Number of subjects: 313
Study 24312450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral lymphocytes (iTuLy)
Number of subjects: 313
Study 24312450 — intervention group
Group type: COMPARATOR
Intervention: Non-LPBC patients
Number of subjects: 313
Study 20299470 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 0
Study 20299470 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-induced weight loss
Number of subjects: 0
Study 20299470 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0
Study 20299470 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (peroxisome proliferator-activated receptor agonist)
Number of subjects: 0
Study 19092464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 1610
Study 19092464 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 1610
Study 19092464 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 1610
Study 16099089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 0
Study 12942405 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice Accepted (AA) - regimens recommended by the expert panel
Number of subjects: 74
Study 12942405 — intervention group
Group type: COMPARATOR
Intervention: Advice Rejected (AR) - regimens per clinician's preference
Number of subjects: 74
Study 10640260 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg zolmitriptan
Number of subjects: 2800
Study 10640260 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan
Number of subjects: 2800
Study 10640260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study 8887580 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mexiletine
Number of subjects: 15
Study 8887580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 15
Study 8887580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1889254 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 10
Study 1889254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3932077 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 8
Study 3932077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 8
Study 3932077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29499792 — intervention group
Group type: EXPERIMENTAL
Intervention: ISI‐Math
Number of subjects: 370
Study 29499792 — intervention group
Group type: COMPARATOR
Intervention: ISI‐Reading
Number of subjects: 370
Study 26642301 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (5 mg)
Number of subjects: 14
Study 26642301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24599353 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch isolation pancreaticoduodenectomy (NT-PD)
Number of subjects: 12
Study 24599353 — intervention group
Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy (ST-PD)
Number of subjects: 12
Study 22688828 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC22A12 SNP rs11602903
Number of subjects: 414
Study 22688828 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC22A12 SNP rs505802
Number of subjects: 414
Study 22688828 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC22A12 SNP rs11231825
Number of subjects: 414
Study 22688828 — intervention group
Group type: COMPARATOR
Intervention: SLC22A12 SNP rs11602903 in African Americans
Number of subjects: 414
Study 20531245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 U intravenously before ERCP)
Number of subjects: 7
Study 20531245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 20531245 — intervention group
Group type: COMPARATOR
Intervention: Gabexate
Number of subjects: 7
Study 18541561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil muffin consumption (sesamin, 94 mg; sesamolin, 42 mg)
Number of subjects: 10
Study 18541561 — intervention group
Group type: COMPARATOR
Intervention: Corn oil muffin consumption
Number of subjects: 10
Study 18541561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil muffin consumption
Number of subjects: 10
Study 17570961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 58
Study 17570961 — intervention group
Group type: COMPARATOR
Intervention: Active social support procedure
Number of subjects: 58
Study 15325678 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 10.4 g/d of fiber
Number of subjects: 56
Study 15325678 — intervention group
Group type: COMPARATOR
Intervention: Diet containing 30.5 g/d of fiber
Number of subjects: 56
Study 11314452 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 250
Study 11314452 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 250
Study 9287967 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms daily)
Number of subjects: 75
Study 9287967 — intervention group
Group type: COMPARATOR
Intervention: Usual medications
Number of subjects: 75
Study 8394061 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg once a day for 6 consecutive days)
Number of subjects: 52
Study 8394061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiemetic treatment)
Number of subjects: 52
Study 2872260 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 238
Study 2872260 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient management
Number of subjects: 238
Study 2872260 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment phase completion
Number of subjects: 238
Study 2872260 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of current episodes of back pain
Number of subjects: 238
Study 31640711 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT+CCRT
Number of subjects: 502
Study 31640711 — intervention group
Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 502
Study 31640711 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional ICT
Number of subjects: 502
Study 29238506 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin, titrated from 300 mg/day to a maximum of 900 mg/day
Number of subjects: 30
Study 29238506 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate, titrated from 50 mg/day to a maximum of 100 mg/day
Number of subjects: 30
Study 29238506 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 30
Study 29238506 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 30
Study 25494032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate supplementation (50 mg · kg·fat‐free‐mass⁻¹ · day⁻¹; n = 7)
Number of subjects: 17
Study 25494032 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 17
Study 23855591 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical therapy program
Number of subjects: 100
Study 23855591 — intervention group
Group type: COMPARATOR
Intervention: Regular physical therapy
Number of subjects: 100
Study 21692299 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (compound general anesthesia with meridian points)
Number of subjects: 90